Skip to main content
Premium Trial:

Request an Annual Quote

Acacia's Patent-Acquisition Subsidiary Licenses Nucleic Acid-Purification IP

This article corrects an earlier version that mistakenly reported that Acacia Technologies subsidiary CombiMatrix licensed the IP.
NEW YORK (GenomeWeb News) — Acacia Research Corporation last week said that Acacia Patent Acquisition Corporation, a wholly owned subsidiary of Acacia Technologies, has acquired rights to patents relating to purifying nucleic acids.
Acacia did not disclose the name of the entity that sold it the IP, but said that the patents “generally relate to methods and equipment used to purify plasmid DNA products.”
The company said the technology could be used to produce "ultrapure pharmaceutical quality nucleic acids for DNA-vaccines and gene therapies” for a variety of diseases.
Financial terms of the agreement were not released.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.